BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
US Army
Express Scripts
Medtronic
Mallinckrodt
Chubb
AstraZeneca
Cipla
Dow

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,193,685

« Back to Dashboard

Which drugs does patent 9,193,685 protect, and when does it expire?

Patent 9,193,685 protects ARISTADA and is included in one NDA.

This patent has seven patent family members in seven countries.
Summary for Patent: 9,193,685
Title:Pharmaceutical compositions having improved storage stability
Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
Inventor(s): Perry; Jason M. (Cambridge, MA), Deaver; Daniel R. (Franklin, MA), Hickey; Magali B. (Westwood, MA), Remenar; Julius F. (Framingham, MA), Vandiver; Jennifer (Arlington, MA), Palmieri, Jr.; Michael J. (Hopkington, MA), Pan; Zhengzheng (Arlington, MA)
Assignee: ALKERMES PHARMA IRELAND LIMITED (Dublin, IE)
Application Number:14/031,842
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 9,193,685

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-001 Oct 5, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-002 Oct 5, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-003 Oct 5, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-004 Jun 5, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF SCHIZOPHRENIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,193,685

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 631345 ➤ Subscribe
Japan 2015529237 ➤ Subscribe
Hong Kong 1210033 ➤ Subscribe
European Patent Office 2897592 ➤ Subscribe
Canada 2885196 ➤ Subscribe
Australia 2013349388 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2014080285 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Boehringer Ingelheim
Citi
US Department of Justice
US Army
Julphar
Novartis
Johnson and Johnson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot